Superbugs focus of new coalition of scientists, biotech leaders

A group of scientists, policy experts and biotech leaders launched a coalition Aug. 21 to combat superbugs.

The Working to Fight AMR coalition will work to raise awareness about antimicrobial resistance and advocate for policies that incentivize drugmakers to develop new antibiotics.  

Coalition members include:

  • Greg Frank, PhD, director of infectious disease policy at the Biotechnology Innovation Organization and director of Working to Fight AMR
  • Aleks Engel, PhD, director of REPAIR Impact Fund at Novo Holdings

  • Julie Louise Gerberding, MD, former CDC director and executive vice president and chief patient officer at Merck

  • Eric Kimble, chief commercial officer at Entasis Therapeutics

  • Werner Lanthaler, PhD, CEO at Evotec

  • Evan Loh, MD, CEO at Paratek Pharmaceuticals and chairman of the Antimicrobials Working Group

  • Kevin Outterson, co-director of the health law program and professor at Boston University School of Law

  • Ruben Tommasi, PhD, chief scientific officer at Entasis Therapeutics

  • Zachary Zimmerman, PhD, CEO at Forge Therapeutics

To learn more about the coalition, click here.

More articles on clinical leadership and infection control:
6 Boston hospital employees on leave amid patient abuse investigation
Northwell graduates 20 ER nurses from sexual assault nurse examiner program
49% of healthcare professionals feel equipped to achieve zero harm, survey finds

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars